Encouraged by the potent cell-toxic effects of CD19-TRAIL in vitro, we next investigated the therapeutic effect of CD19-TRAIL in vivo in BCP-ALL xenograft models. This evidence concerns the gene TNFSF10 and acute lymphoblastic leukemia.